Advancing Biosimilar Development Using Pharmacodynamic Biomarkers in Clinical Pharmacology Studies
Junyi Li1, Jeffry Florian1, Elizabeth Campbell1
1Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
No abstract available in PubMed .
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Measurement of Bioavailability: Pharmacodynamic Methods
Drug Products: Biologics, Biosimilars and Interchangeables
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Dosage Regimens: Partial Pharmacokinetic Parameters
Bioavailability Study Design: Single Versus Multiple Dose Studies
Preclinical Development: Overview
